The distinction between metastatic adenocarcinomas of lung (LAC), breast (BAC), and ovary (OAC) in serous effusions can be very difficult since they all can present as tight cell clusters. This is particularly challenging when the malignant effusion is the patient's initial presentation or when the patient has a history of more than one primary. The aim of this study is to evaluate the usefulness of WT1, monoclonal CEA (mCEA), TTF1, and CA125 antibodies in the differential diagnosis of metastatic adenocarcinoma from the lung, breast and ovary in serous effusions.
Introduction
Malignant serous effusion is not an uncommon clinical manifestation of adenocarcinoma. 1, 2 The distinction between metastatic adenocarcinomas of lung (LAC), breast (BAC), and ovary (OAC) in serous effusions could be very difficult or sometimes impossible on the basis of morphology alone. [1] [2] [3] This is particularly challenging when the malignant effusion is the patient's initial presentation or when the patient has a history of more than one primary. However, elucidating the origin of these malignant neoplasms often may have therapeutic consequences for the patient. 4 Many antibodies directed against specific cell type antigens have been used in LAC, BAC, and OAC on the histological section and/or serous effusions to enhance the pathological diagnosis, with varying degrees of efficacy but the optimum panel of antibodies is yet to be reported. When used in specific panels, immunohistochemical studies can be extremely useful for determining tumor type, particularly in cases with an unknown primary site. [5] [6] [7] [8] WT1, a tumor suppressor gene initially identified as contributing to the development of Wilms tumor, is expressed preferentially in the urogenital system and mesoderm-derived tissues. 9, 10 Relatively specific reactivity for WT1 protein has been shown in ovarian papillary serous carcinoma and in a number of different carcinomas in addition to mesothelioma, desmoplastic small round cell tumor, and Wilms tumor. [11] [12] [13] There are no specific markers of ovarian adenocarcinoma, one of the most common neoplasms to present with ascites. Antibodies such as CA125 and human alveolar macrophage (HAM) 56 have been proposed as useful markers of ovarian adenocarcinoma, but immunoreactivity is often present in adenocarcinomas of other sites, limiting their diagnostic value. 12, 14, 15 Thyroid transcription factor1 (TTF-1) has been described as a marker that reportedly recognizes carcinomas of pulmonary origin, particularly pulmonary adenocarcinoma. [16] [17] [18] TTF-1 is also expressed in the thyroid gland, the diencephalon, and the bronchioalveolar epithelium. [18] [19] [20] [21] Monoclonal carcinoembryonic antigens (mCEA) are of value in confirmation of an adenocarcinoma, as they are commonly positive in these neoplasms but rarely so in reactive mesothelial cells or mesothelioma. 15, 22 However, certain adenocarcinomas, especially ovarian serous adenocarcinomas, are characteristically negative with mCEA. 15 The aim of this study was to evaluate the usefulness of WT1, monoclonal CEA (mCEA), TTF1, and CA125 antibodies as markers in the differential diagnosis of ovarian, lung, and breast metastatic adenocarcinomas in cytologic material prepared from malignant effusion specimens.
Materials and Methods
A total of 46 cases of serous effusions were retrieved from our hospital computer system, including 13 BACs, 13 LACs, and 20 OACs. The diagnosis of each case was confirmed by surgical excision and histologic examination of the primary tumor. Formalin-fixed and paraffin-embedded cell block sections from the serous effusions were stained with hematoxylin and eosin to evaluate the presence of tumor cells in each cell block. Immunohistochemical staining was performed on the DAKO Autostainer (DAKO, Carpinteria, CA) using DAKO LSABþ and 3,3 0 -diaminobenzidine as the chromogen. Deparaffinized sections of formalin-fixed tissue at 4-lm thickness were stained with H&E or labeled with anti-WT1 (1:50; Cell Marque, Hot Springs, AR), anti-TTF1 (1:200; DAKO Cytomation, Carpinteria, CA), anti-mCEA (1:1; Cell Marque), and anti-CA125 (1:100; Vector Laboratories, Newcastle upon Tyne, UK) along with positive and negative controls. Citrate antigen retrieval (20 min) was used before incubation with antibodies. An appropriate positive control slide for each marker evaluated was included in each run. Control slides substituting tris buffer for primary antibody were run as negative controls. Two observers (WZ & CWM) blindly reviewed the immunostaining without knowledge of the previous clinical or histopathologic diagnoses. At least 200 cells were counted and the extent of staining was assessed as percentage of neoplastic cells, and intensity of staining was graded on a 0 to 3þ scale semiquantitatively (negative, 0; weak, 1þ; moderate, 2þ; strong, 3þ). The distribution pattern of immunoreactivity for WT1 and TTF1 was recorded as nuclear, and mCEA and CA125 as membranous staining.
Results
Immunoreactivity for WT1, CA125, TTF1, and mCEA was studied in a total of 46 cases of metastatic adenocarcinoma in cell blocks prepared from serous effusions, including 13 BACs, 13 LACs, and 20 OACs. Overall results are summarized in Table I .
WT1
WT1 immunoreactivity was detected in 19/20 (95%) OCA cases, exhibiting an immunoreactivity in at least 56.6% of neoplastic cells (Fig. C-1 Figs. C-1-C-5. around the tumor cell aggregates (Fig. C-2 ). CA125 was positive in 8/13 (62%) LAC and 6/13 (46%) BAC cases, with a similar staining pattern as the tumor cells in ovary.
In the positively staining lung and breast cases, about 70.6% and 90% neoplastic cells were stained with CA125, respectively. Although OAC showed a uniformly 3þ staining, there is no significant difference in the staining intensity in comparison with LAC (2.88) and BAC (2.83) cases.
TTF1
TTF1 immunoreactivity was detected in 9/13 (69%) LAC with the characteristic nuclear staining pattern and an average of 2.0 intensity (Fig. C-3 ). No nuclear immunostaining was detected in either the OAC (0/20, 0%) or BAC cases (0/13, 0%).
mCEA mCEA immunoreactivity with a membranous staining pattern was detected in 8/13 (62%) LAC and in 6/13 (46%) BAC cases (Figs. C-4 and C-5). The average staining intensity was 2.75 for both LAC and 2.67 for BAC. In contrast, there is negative immunoreaction with mCEA for all 20 OAC cases.
Discussion
Serous effusions may be the first symptom of both mesotheliomas and metastatic adenocarcinomas. In these circumstances, cytology can play a critical role in the diagnosis. The initial challenge is to distinguish the malignant mesothelioma (MM) from metastatic adenocarcinoma in cytologic specimens, which is aided greatly by the use of a panel of antibody immunocytochemistry. [1] [2] [3] [4] [5] [6] [7] [8] The next challenge is to identify the primary neoplasm in the case of adenocarcinoma manifesting initially as an effusion or if the patient has a history of more than one primary. In this study, we evaluated the usefulness of WT1, monoclonal CEA (mCEA), TTF1, and CA125 antibodies in the differential diagnosis of metastatic LAC, BAC, and OAC in serous effusions.
WT1 is a tumor suppressor gene implicated in the development of Wilms tumor and has been demonstrated in a high percentage of OAC and in some BAC. [11] [12] [13] The frequent expression of WT1 in ovarian serous and transitional cell carcinomas, and its infrequent expression in other ovarian carcinoma subtypes, such as clear cell, mucinous, and endometrioid adenocarcinomas, has been well documented. 10 Our study demonstrates that WT-1 is a highly sensitive marker of OAC and its expression is only seen in a small fraction of lung and breast carcinomas (23 and 15%, respectively). However, there was no significant difference noted in the intensity and the percentage of stained neoplastic cells in any of the immunoreactive BAC and LAC cases when compared with OAC. These results are in agreement with previous studies. [9] [10] [11] [12] [13] 15, 18 In addition to being a sensitive marker of ovarian serous carcinomas in the workup of carcinoma of unknown primary, WT-1 is also a relatively specific ovarian marker. We believe that WT-1 should be included in the immunostaining panel of malignant effusions of unknown primary and that a negative reaction would argue strongly against the diagnosis of OAC.
Overall, 69% of primary pulmonary adenocarcinomas showed staining for TTF-1, and no immunoreactivity was noted in ovarian and breast carcinomas. TTF1 immunostaining was characterized by a nuclear pattern in 69% of tumor cells, with a moderate intensity (2.0). Our data are very close to the findings of several previous reports, where the range of positive reaction was 72-80%, and is also consistent with the almost universal finding that anti-TTF-1 only stains adenocarcinomas that are primary in the lung and thyroid gland. [16] [17] [18] [19] [20] [21] [22] The usefulness of TTF-1 as a marker of pulmonary adenocarcinoma diagnosis is confirmed by our study, although it is limited by the sensitivity of TTF1 staining. 16, 17 TTF-1 is the best marker to confirm the diagnosis of LAC; however, a negative TTF-1 expression does not rule out a lung primary and a panel of antibodies will be an important part in determining the primary site.
CEA is a glycoprotein within a large family of glycoproteins, which is expressed in adenocarcinomas in a variable percentage, depending on the monoclonal or polyclonal antibodies. The percentage of carcinomas positive for CEA is variable, depending on the primary site and the subtype of carcinoma. 15, 22 Our study demonstrated that a membranous mCEA expression pattern was found in 8/12 (67%) LAC and 6/13 (46%) BAC, but no mCEA immunoreactivity was detected in OAC. This finding supports the value of monoclonal carcinoembryonic antigen (mCEA) in the differential diagnosis as it is commonly positive in breast and lung carcinomas, while characteristically negative in ovarian serous adenocarcinoma. Therefore, CEA is one of the best negative antibodies for OAC, and a positive expression of mCEA in the metastatic neoplastic cells argues against such diagnosis. It is worth noting that this stands true only for the serous type and that mucinous ovarian adenocarcinomas can be positive for mCEA and negative for WT-1. In addition, our findings revealed that there is a much higher expression of mCEA in LAC than BAC.
To date, there are no specific markers of ovarian adenocarcinoma which is one of the most common neoplasms to present with ascites. 11, 12 CA125 is a glycoprotein identified on the cell membrane in celomic epithelium during embryogenesis, expressed in a high percentage of ovarian carcinomas. More than 90% of ovarian cancers and 10-30% of primary breast cancers have been reported to express CA125. 15 The expression of CA125 has also been detected in tissue sections of numerous other tumors, including those of lung, stomach, pancreas, and mesothelium, limiting its diagnostic value. [12] [13] [14] [15] Our study showed that CA125 was expressed in 20/20 OCA cases (100%) with a characteristic membranous staining pattern, rimming around the tumor cell aggregates as compared with 8/13 (61.5%) of metastatic lung cancers and 6/13 (46%) of metastatic breast cancers. CA125 demonstrates a typically strong and diffuse pattern in metastatic ovary and breast carcinomas, in contrast with a relatively focal staining pattern in the metastatic lung carcinoma.
In conclusion, positive immunoreactivity for WT1 and/ or CA125 with a negative reaction to CEA would be supportive of an OAC particularly in a peritoneal fluid. A positive CEA argues against the diagnosis of OAC of the serous type. In the event of a positive CEA, TTF-1 would be useful in confirming a LAC particularly in a pleural fluid (Fig. 1) . BAC is less likely to express CEA and WT-1 than LAC.
